Topics in multiple myeloma discussed at ASCO 2016
How combining an evolutionary perspective with genomic methods can advance CLL treatment
The potential impact of biosimilars in hematology
What’s new in minimal residual disease (MRD) detection in myeloma?
The Society of Hematologic Oncology (SOHO)
Hagop M. Kantarjian